Argatroban Injection
Product Images NDC 83301-0500

This is a data table showing information related to the prediction of Warfarin INR with and without the addition of Argatroban. The data includes error values associated with the prediction of INR for both cases. The study involves 24 subjects and provides insights into the impact of these treatments on thromboplastin levels. This data can be useful for understanding the efficacy of combining Warfarin with Argatroban in managing INR levels in patients.*

This text provides data on the proportion of event-free individuals in Study 1, comparing Argatroban treatment group (N=160, censored = 119%) with a Historical Control group (N=147, censored = 90%). The p-value for this comparison is 0.007.*

The text provides details about an evaluation of the proportion of event-free outcomes in Study 1. It includes information on the number of participants in the study, the number censored, and the p-value obtained from the analysis. Additionally, there are numerical values indicating the event-free proportions at different time points in the study.*

This is a detailed description of Argatroban Injection, a medication used for intravenous infusion only. The medication comes in a 50mL single-dose vial and each mL contains 1mg of Argatroban along with Propylene Glycol, Dehydrated Alcohol, and Sodium Chloride. It is important to note that the solution should not be diluted prior to administration, and any unused portion should be discarded. The medication does not contain preservatives, and it should not be used if the solution is cloudy or contains a precipitate. The usual adult dosage can be found in the package insert. It is recommended to store the medication at 20° to 25°C and protect it from light by retaining it in the carton. The manufacturing details indicate that it is Manufactured for Mullan Pharmaceutical Inc. in Pasadena, CA and Manufactured by Gland Pharma Limited in Hyderabad, India.*